Publication details

The First Registry. Comparison of anticoagulant treatment in patients with atrial fibrillation

Authors

ŠPINAR Jindřich VÍTOVEC Jiří SOUČEK Miroslav ŠPINAROVÁ Lenka LÁBROVÁ Růžena ŠIŠÁKOVÁ Martina JARKOVSKÝ Jiří ŠPÁC Jiří ONDREJKOVÁ Alena

Year of publication 2014
Type Article in Periodical
Magazine / Source Experimental and Clinical Cardiology
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords Atrial fibrillation; Bleeding; Dabigatran; Risk; Warfarin
Description Aim: The FIRST registry aimed to compare patients with atrial fibrillation treated with dabigatran or warfarin. Methods: The study was performed in 10 centres in the Czech Republic. Results: Upon enrolment, 33.2% and 35.6% of patients respectively showed sinus rhythm. The last dose of warfarin before changing to dabigatran was higher than the maintenance dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients did not differ in the CHA2DS2-VASc score. The principal difference was in the HAS BLED score: 55.3% of patients treated with dabigatran demonstrated a score of three or more while only 33.5% of those treated with warfarin did (p < 0.001). In 14.7% of patients treated with dabigatran, serious bleeding was observed during the previous treatment with warfarin. In patients treated with warfarin serious bleeding occurred in 2.0%. The most frequent reason (56.6%) for changing over to dabigatran was the impossibility to maintain INR within the therapeutic range. Conclusion: Patients are transferred from warfarin to dabigatran in particular due to the impossibility to maintain INR within the therapeutic range, and these are more frequently patients with a higher bleeding risk.

You are running an old browser version. We recommend updating your browser to its latest version.

More info